On January 3, 2024 Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, reported the completion of a $52.5 million Series A financing (Press release, Radionetics Oncology, JAN 3, 2024, View Source [SID1234638939]). The round was led by Frazier Life Sciences, 5AM Ventures, and new investor, DCVC Bio, with participation from Crinetics Pharmaceuticals, and GordonMD Global Investments, bringing the total raised to date to $82.5 million. Radionetics plans to use the proceeds to advance its pipeline of potent, small molecule radiopharmaceuticals targeting novel G-protein coupled receptors (GPCRs) for the treatment of a broad range of cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Powered by a team with a unique expertise in radiopharmaceuticals, GPCR biology, and small molecule chemistry, Radionetics is well-positioned to be a leader in the development of first-in-class radiopharmaceuticals," said Eric Shiozaki, Ph.D., Partner at DCVC Bio and newly appointed Director of Radionetics Oncology. "We are excited to support Radionetics in their pursuit of developing novel and potentially life-changing radiopharmaceuticals for cancer patients."
Concurrent with the financing, Radionetics Oncology also announced the appointment of Paul Grayson as the company’s Chief Executive Officer. Paul brings a wealth of knowledge across a broad range of technologies from his time leading cutting-edge biotech companies over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences additionally include founding roles at Fate Therapeutics (NASDAQ: FATE), BirdRock Bio (acquired by Skye Biosciences), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).
"I’m thrilled to join Radionetics at such an exciting time in the evolution of the company and radiopharmaceutical therapeutics," said Paul Grayson, President and Chief Executive Officer. "The spatial biology and pharmacology of GPCRs makes them ideal for small molecule radiopharmaceutical development, opening a new chapter for the field."